Myelodysplastic Syndrome Market Report 2026

Myelodysplastic Syndrome Market Overview

• Myelodysplastic Syndrome market size has reached to $2.85 billion in 2025 • Expected to grow to $4.65 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Rising Incidence Of Rare Blood Cancers Boosts Growth In The Myelodysplastic Syndrome (MDS) Market • Market Trend: Bristol Myers Squibb Gains FDA Approval for Reblozyl as First-Line Therapy for Anemia in Myelodysplastic Syndrome Patients • North America was the largest region in 2025.

What Is Covered Under Myelodysplastic Syndrome Market?

Myelodysplastic syndrome (MDS) is a group of disorders characterized by the malfunctioning or abnormal development of bone marrow cells, leading to ineffective blood cell production. Myelodysplastic syndrome treatment improves blood cell counts, alleviates symptoms and delays disease progression. Myelodysplastic syndrome (MDS) can progress to acute myeloid leukemia (AML), a more aggressive form of blood cancer. The main types of myelodysplastic syndrome are myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia and myelodysplastic syndrome with ring sideroblasts, among others. Myelodysplastic syndrome (MDS) with unilineage dysplasia refers to a specific subtype or classification within the spectrum of myelodysplastic syndrome (MDS). The various drugs include azacitidine, lenalidomide, decitabine and deferasirox. The various treatment includes supportive therapy, growth factors, chemotherapy, stem cell transplant and others. The various route of administration includes oral, injectable and other routes of administration. These are used by various end-users such as hospitals, homecare, specialty centers and others.

What Is The Myelodysplastic Syndrome Market Growth Forecast?

The myelodysplastic syndrome market size is expected to see rapid growth in the next few years. It will grow to $4.65 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to growth in targeted therapies, expansion of precision medicine solutions, increased investment in oncology r&d, advancements in stem cell transplantation, rising adoption of oral hypomethylating drugs. Major trends in the forecast period include increasing adoption of hypomethylating agents, growing use of combination therapy approaches, rising focus on early detection and diagnostic accuracy, expansion of stem cell transplantation and regenerative options, increasing demand for supportive care and growth factor therapies.

Global Myelodysplastic Syndrome Market Segmentation

1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia, Myelodysplastic Syndrome With Multilineage Dysplasia, Myelodysplastic Syndrome With Ring Sideroblasts, Other Types 2) By Drug: Azacitidine, Lenalidomide, Decitabine, Deferasirox 3) By Treatment: Supportive Therapy, Growth Factors, Chemotherapy, Stem Cell Transplant, Other Treatments 4) By Route Of Administration: Oral, Injectable, Other Routes Of Administrations 5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users Subsegments: 1) By Myelodysplastic Syndrome With Unilineage Dysplasia: Type Of Dysplasia, Patient Demographics 2) By Myelodysplastic Syndrome With Multilineage Dysplasia: Severity Of Dysplasia, Patient Demographics 3) By Myelodysplastic Syndrome With Ring Sideroblasts: Percentage Of Ring Sideroblasts, Treatment Options 4) By Other Types: Specific Types, Treatment Options

What Is The Driver Of The Myelodysplastic Syndrome Market?

The increasing incidence of rare blood cancers is expected to propel the growth of the myelodysplastic syndrome (MDS) market going forward. Blood cancers are types of hematologic malignancies with a low incidence rate in the population and originate from the cells of the bone marrow, lymph nodes and other components of the blood and immune system. Myelodysplastic syndrome (MDS) treatment aims to manage the condition by improving blood cell production and addressing associated symptoms to prevent the progression of blood cancer in the bone marrow. For instance, in September 2024, according to the Leukemia and Lymphoma Society, a US-based professional organization company Every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma. In 2024, an estimated 187,740 individuals will face these cancers, representing 9.4% of the expected 2,001,140 new cancer cases in the US. Therefore, the increasing incidence of blood cancer drives the growth of the myelodysplastic syndrome (MDS) market.

Key Players In The Global Myelodysplastic Syndrome Market

Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

Global Myelodysplastic Syndrome Market Trends and Insights

Major companies operating in the myelodysplastic syndrome (MDS) market are focusing on developing innovative advancements such as first-line erythroid maturation therapies to improve anemia management and reduce reliance on recurrent red blood cell transfusions. First-line erythroid maturation therapies refer to targeted treatments that enhance late-stage red blood cell development, enabling earlier and more durable correction of anemia in patients who have not yet received erythropoiesis-stimulating agents. For instance, in August 2023, Bristol Myers Squibb, a US-based pharmaceutical industry company, gets FDA approval for Reblozyl (luspatercept-aamt) as a first-line treatment for anemia in ESA-naïve adults with low- to intermediate-risk myelodysplastic syndromes (MDS) who may need regular RBC transfusions. In the Phase 3 COMMANDS trial, Reblozyl showed superior efficacy in achieving RBC transfusion independence and hemoglobin increase over epoetin alfa, addressing anemia earlier in a broader range of patients.

What Are Latest Mergers And Acquisitions In The Myelodysplastic Syndrome Market?

In October 2025, Launch One Acquisition Corp., a United States–based special purpose acquisition company focused on healthcare and technology investments, entered into a business combination agreement with Minovia Therapeutics to create a Nasdaq-listed biotechnology company specializing in mitochondrial augmentation therapies. With this transaction, Launch One aims to support Minovia’s capital requirements, accelerate its clinical development programs, and facilitate its transition into a publicly traded entity. Minovia Therapeutics is an Israel-based clinical-stage biotechnology company developing mitochondrial cell therapies for rare diseases, including Pearson Syndrome and Myelodysplastic Syndrome.

Regional Outlook

North America was the largest region in the myelodysplastic syndrome market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Myelodysplastic Syndrome Market?

The myelodysplastic syndrome (MDS) market consists of revenues earned by entities by providing experimental therapies, targeted therapies and blood transfusion. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelodysplastic syndrome (MDS) market also consists of sales of erythropoiesis-stimulating agents (ESAs) and immunomodulatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Myelodysplastic Syndrome Market Report 2026?

The myelodysplastic syndrome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the myelodysplastic syndrome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.